Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker AZN · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | An Efficacy and Safety Study to Assess an Inhaled, Fixed-dose, Budesonide/Formoterol Fumarate in Pa… NCT07934420 · Asthma BFF MDI, BD MDI | AZN AstraZeneca | Phase 3 | Not yet recruiting | 216 | Jul 30, 2029 | Registry ↗ |
| Nov 13, 2026 | A Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD… NCT07812077 · Healthy Participants [14C]AZD4954 Oral Solution, AZD4954 film-coated tablet | AZN AstraZeneca | Phase 1 | Recruiting was not yet recruiting | 16 | Mar 17, 2027 | Registry ↗ |
| Nov 13, 2026 | Long-term Safety of Eplontersen Treated aTTR Patients and in Liver Transplant and Severely Hepatic… NCT07654855 · Transthyretin Amyloidosis, Transthyretin Amyloidosis With C… None ( observational study ) | AZN AstraZeneca | — | Recruiting | 320 | Jan 29, 2032 | Registry ↗ |
| Nov 13, 2026 | Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fa… NCT07444567 · Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA) Benralizumab | AZN AstraZeneca | Phase 3 | Recruiting | 230 | Dec 27, 2029 | Registry ↗ |
| Nov 13, 2026 | A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve a… NCT07430306 · Systemic Lupus Erythematosus Anifrolumab | AZN AstraZeneca | Phase 3 | Recruiting | 245 | Jan 26, 2029 | Registry ↗ |
| Nov 13, 2026 | Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Ly… NCT07109219 · B-cell Acute Lymphoblastic Leukemia (B-ALL) AZD4512 monotherapy | AZN AstraZeneca | Phase 1/2 | Recruiting | 83 | Oct 11, 2028 | Registry ↗ |
| Nov 13, 2026 | Clinical and Demographic Characteristics of Adult p Atients With NEurofibromatosis in RUSsia NCT07088991 · Neurofibromatosis | AZN AstraZeneca | — | Recruiting | 200 | Mar 31, 2028 | Registry ↗ |
| Nov 13, 2026 | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dysl… NCT06834932 · Dyslipidaemia Placebo, Rosuvastatin Dose 1 | AZN AstraZeneca | Phase 2/3 | Active, not recruiting | 432 | Feb 22, 2027 | Registry ↗ |
| Nov 13, 2026 | Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid… NCT06218914 · Non-small Cell Lung Cancer, Colorectal Carcinoma NT-112: Autologous, engineered T Cells targeting KRAS G12D,… | AZN AstraZeneca | Phase 1 | Active, not recruiting was recruiting | 108 | Aug 30, 2027 | Registry ↗ |
| Nov 13, 2026 | A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreate… NCT05057494 · Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Acalabrutinib, Venetoclax | AZN AstraZeneca | Phase 3 | Active, not recruiting | 607 | Jul 15, 2027 | Registry ↗ |
| Nov 13, 2026 | Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics NCT03953300 · Asthma Benralizumab, Placebo | AZN AstraZeneca | Phase 4 | Completed was active, not recruiting | 75 | Oct 20, 2026 | Registry ↗ |
| Nov 12, 2026 | Changes in Symptom and Quality of Life in Patients With Uncontrolled Asthma Treated With Budesonide… NCT07933510 · Asthma, Uncontrolled Asthma Budesonide/Glycopyrronium/Formoterol fumarate metered dose… | AZN AstraZeneca | — | Not yet recruiting | 200 | Aug 31, 2027 | Registry ↗ |
| Nov 12, 2026 | A Modular, Phase I/II Study to Evaluate CT204V-CD19 x CD20 in Participants With Relapsed or Refract… NCT07932496 · Relapsed or Refractory B-Cell Malignancies CT204V-CD19 × CD20 | AZN AstraZeneca | Phase 1/2 | Not yet recruiting | 160 | Oct 15, 2029 | Registry ↗ |
| Nov 12, 2026 | A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat,… NCT07930507 · Hypercholesterolemia Laroprovstat, Rosuvastatin 1 | AZN AstraZeneca | Phase 3 | Not yet recruiting | 204 | Oct 11, 2027 | Registry ↗ |
| Nov 12, 2026 | A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatm… NCT07520162 · Chronic Rhinosinusitis With Nasal Polyps Tezepelumab | AZN AstraZeneca | Phase 3 | Recruiting | 230 | Mar 1, 2028 | Registry ↗ |
| Nov 12, 2026 | A Study to Investigate Safety, Tolerability, PK, and PD of AZD4248 in Healthy Participants, Partici… NCT07024823 · Chronic Kidney Disease AZD4248, Placebo | AZN AstraZeneca | Phase 1 | Recruiting | 192 | Jan 29, 2027 | Registry ↗ |
| Nov 12, 2026 | REAL-WORLD DURVALUMAB IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER NCT06826677 · Small Cell Lung Carcinoma Durvalumab | AZN AstraZeneca | — | Completed | 71 | Jan 23, 2025 | Registry ↗ |
| Nov 12, 2026 | AZD5305 hADME in Patients With Advanced Solid Malignancies NCT06713369 · Locally Advanced or Metastatic Solid Tumor Saruparib (AZD5305), [14C]-AZD5305 microtracer | AZN AstraZeneca | Phase 1 | Recruiting | 8 | Dec 31, 2026 | Registry ↗ |
| Nov 12, 2026 | Real-world Study Assessing Efficacy of TezepeLumaB in Patients With Severe Asthma Regardless of Phe… NCT06566885 · Severe Asthma | AZN AstraZeneca | — | Completed was active, not recruiting | 125 | Oct 20, 2026 | Registry ↗ |
| Nov 12, 2026 | A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/… NCT06015737 · Cutaneous Lupus Erythematosus Anifrolumab, Placebo | AZN AstraZeneca | Phase 3 | Active, not recruiting | 339 | Nov 2, 2026 | Registry ↗ |
| Nov 12, 2026 | Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Ne… NCT04924608 · Neurofibromatosis 1, Plexiform Neurofibroma (PN) Selumetinib, Placebo | AZN AstraZeneca | Phase 3 | Active, not recruiting | 145 | Aug 5, 2024 | Registry ↗ |
| Nov 12, 2026 | A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advan… NCT04739761 · Breast Cancer Trastuzumab Deruxtecan | AZN AstraZeneca | Phase 3 | Active, not recruiting | 506 | Feb 8, 2024 | Registry ↗ |
| Nov 12, 2026 | A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer NCT03742102 · Triple Negative Breast Neoplasms Durvalumab, Capivasertib | AZN AstraZeneca | Phase 1/2 | Active, not recruiting | 243 | Nov 29, 2024 | Registry ↗ |
| Nov 10, 2026 | Tezepelumab CRSwNP Real World Study (CREW Study) NCT07790198 · Chronic Rhinosinusitis With Nasal Polyps Tezepelumab | AZN AstraZeneca | — | Not yet recruiting | 100 | Sep 30, 2028 | Registry ↗ |
| Nov 10, 2026 | Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saph… NCT07691970 · Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lu… Anifrolumab, Anifrolumab | AZN AstraZeneca | Phase 3 | Recruiting | 1,072 | Dec 30, 2032 | Registry ↗ |
| Nov 10, 2026 | A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Parti… NCT07534592 · Healthy Participants Elecoglipron, Atorvastatin | AZN AstraZeneca | Phase 1 | Active, not recruiting | 48 | Jan 25, 2027 | Registry ↗ |
| Nov 10, 2026 | A Study of AZD0120 in Autoimmune Diseases NCT07295847 · Systemic Sclerosis, Idiopathic Inflammatory Myopathies AZD0120, SOC | AZN AstraZeneca | Phase 1/2 | Recruiting | 27 | Feb 22, 2028 | Registry ↗ |
| Nov 10, 2026 | Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Adv… NCT07291037 · Non-small Cell Lung Cancer (NSCLC) Datopotamab deruxtecan (Dato-DXd), Docetaxel | AZN AstraZeneca | Phase 3 | Recruiting | 400 | Jan 29, 2029 | Registry ↗ |
| Nov 10, 2026 | Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody NCT07285213 · Clostridioides Difficile Infection AZD5148, Placebo | AZN AstraZeneca | Phase 2 | Recruiting | 230 | Apr 20, 2027 | Registry ↗ |
| Nov 10, 2026 | Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With… NCT07069829 · Chronic Obstructive Pulmonary Disease | AZN AstraZeneca | — | Recruiting | 1,400 | Dec 31, 2027 | Registry ↗ |
| Nov 10, 2026 | Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerabi… NCT06576765 · Hepatic Impairment AZD0780 | AZN AstraZeneca | Phase 1 | Completed | 16 | Nov 8, 2024 | Registry ↗ |
| Nov 10, 2026 | Phase IIa Study Evaluating AZD7798 in Crohn's Disease NCT06450197 · Moderate to Severe Crohn's Disease AZD7798, Placebo | AZN AstraZeneca | Phase 2 | Active, not recruiting | 120 | Apr 30, 2026 | Registry ↗ |
| Nov 10, 2026 | Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participa… NCT06307665 · Asthma BDA MDI, AS MDI | AZN AstraZeneca | Phase 3 | Recruiting | 440 | Oct 13, 2027 | Registry ↗ |
| Nov 10, 2026 | Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receivin… NCT06120491 · Metastatic Castration-Sensitive Prostate Cancer Saruparib, Placebo | AZN AstraZeneca | Phase 3 | Active, not recruiting | 1,898 | Sep 30, 2027 | Registry ↗ |
| Nov 10, 2026 | Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) NCT06079671 · Locally Advanced Cervical Cancer Volrustomig, Placebo | AZN AstraZeneca | Phase 3 | Recruiting | 800 | Nov 26, 2027 | Registry ↗ |
| Nov 10, 2026 | A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 t… NCT06023589 · Asthma Tezepelumab, Placebo | AZN AstraZeneca | Phase 3 | Recruiting | 231 | May 31, 2028 | Registry ↗ |
| Nov 10, 2026 | A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metast… NCT04995523 · Non-Small-Cell Lung Carcinoma AZD2936 | AZN AstraZeneca | Phase 1/2 | Active, not recruiting | 212 | Jun 1, 2028 | Registry ↗ |
| Nov 9, 2026 | Study of Safety and PK of AZD0543 in Healthy Adults NCT07824622 · Human Metapneumovirus Infection AZD0543, Placebo | AZN AstraZeneca | Phase 1 | Recruiting | 144 | Mar 24, 2027 | Registry ↗ |
| Nov 9, 2026 | A Study in Greece Observing How Patients With Stomach and Esophageal Cancer Are Diagnosed and Treat… NCT07800754 · Gastric Cancer, Gastroesophageal Junction Cancer | AZN AstraZeneca | — | Recruiting | 300 | Dec 31, 2027 | Registry ↗ |
| Nov 9, 2026 | A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participan… NCT07776509 · Obesity or Overweight, Weight-Related Comorbidity Lenbelintide, Placebo | AZN AstraZeneca | Phase 3 | Recruiting | 500 | Aug 9, 2028 | Registry ↗ |
| Nov 9, 2026 | A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity o… NCT07775404 · Obesity, Overweight Elecoglipron, Placebo | AZN AstraZeneca | Phase 3 | Recruiting | 351 | Apr 6, 2028 | Registry ↗ |
| Nov 9, 2026 | A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in He… NCT07511205 · Healthy Participants, Obesity AZD1043, Placebo | AZN AstraZeneca | Phase 1 | Recruiting | 104 | Apr 9, 2027 | Registry ↗ |
| Nov 9, 2026 | A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH NCT07000136 · Heterozygous Familial Hypercholesterolaemia AZD0780, Placebo | AZN AstraZeneca | Phase 3 | Active, not recruiting | 473 | Jan 4, 2027 | Registry ↗ |
| Nov 9, 2026 | A Multicentre, Single Arm, Non-interventional, Real-world Study to Assess Demographic Characteristi… NCT06862206 · Severe Eosinophilic Asthma benralizumab | AZN AstraZeneca | — | Recruiting | 700 | Jan 31, 2028 | Registry ↗ |
| Nov 9, 2026 | Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab. NCT04157348 · Eosinophilic Granulomatous Vasculitis Benralizumab, Mepolizumab | AZN AstraZeneca | Phase 3 | Active, not recruiting | 140 | Aug 10, 2023 | Registry ↗ |
| Nov 9, 2026 | Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unre… NCT03833154 · Carcinoma, Non-Small-Cell Lung Durvalumab, Placebo | AZN AstraZeneca | Phase 3 | Active, not recruiting | 724 | Oct 31, 2028 | Registry ↗ |
| Nov 9, 2026 | Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Lin… NCT01933932 · Locally Advanced or Metastatic Non Small Cell Lung Cancer S… Selumetinib, Docetaxel | AZN AstraZeneca | Phase 3 | Active, not recruiting | 510 | Jun 7, 2016 | Registry ↗ |
| Nov 6, 2026 | A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults… NCT07922330 · Obesity, Overweight AZD6234, Placebo | AZN AstraZeneca | Phase 3 | Not yet recruiting | 330 | Sep 15, 2028 | Registry ↗ |
| Nov 6, 2026 | A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in… NCT07877818 · Gastric, Esophagogastric Junction FLOT Chemotherapy, Durvalumab | AZN AstraZeneca | Phase 3 | Recruiting was not yet recruiting | 140 | Nov 1, 2029 | Registry ↗ |
| Nov 6, 2026 | Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination De… NCT07851025 · Epithelial Ovarian Cancer Torvutatug samrotecan, Bevacizumab | AZN AstraZeneca | Phase 3 | Recruiting | 950 | Jun 28, 2030 | Registry ↗ |
The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 9:53 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances